Correlation analysis of serum Fractalkine and AHO3 levels with the prognosis of acute cerebral infarction patients after intravenous thrombolysis
Serum Fractalkine and AHO3 levels in prognosis of ACI
Abstract
Objective To examine the association between the prognosis of patients with acute cerebral infarction (ACI) following intravenous thrombolysis and the levels of blood AHO3 and Fractalkine.
Methods A total of 322 patients with acute cerebral infarction (ACI) who underwent intravenous thrombolysis at this hospital from May 2023 to May 2025 were selected as research subjects. Based on the National Institutes of Health Stroke Scale (NIHSS) score at admission, the patients were classified into three groups: severe, moderate, and mild. Using the modified Rankin scale, the patients' prognosis was assessed throughout a 90-day follow-up period. There were two groups of patients: those with a fair prognosis and those with a poor prognosis. Patients with varying degrees of illness severity had their serum levels of AHO3 and Fractalkine compared. The relationship between the severity of ACI and the levels of serum AHO3 and Fractalkine was examined using Spearman correlation analysis. The factors predicting poor prognosis following intravenous thrombolysis in ACI patients were examined using multivariate logistic regression, and the clinical data of the groups with excellent and poor prognoses were compared. Serum levels of AHO3 and Fractalkine alone and together were analyzed using a receiver operating characteristic (ROC) curve to predict poor outcome in patients with ACI following intravenous thrombolysis.
Results There were 174 patients in the mild group, 102 patients in the intermediate group, and 46 patients in the severe group. The moderate group's serum AHO3 level was lower than the mild group's (P<0.010), while the severe group's serum AHO3 level was lower than both groups' (P<0.010). The moderate group had a higher serum Fractalkine level than the mild group, and the severe group had a higher serum Fractalkine level than the moderate and mild groups (P<0.010). The degree of ACI in patients was positively connected with the blood Fractalkine level (rs = 0.594, P = 0.001) and negatively connected with the serum AHO3 level (rs = -0.528, P = 0.007). A lower serum AHO3 level was found in the prognosis poor group compared to the prognosis good group (P<0.05). Furthermore, the serum Fractalkine level and admission NIHSS score of the prognosis poor group were greater than those of the prognosis excellent group, and their age was higher (P<0.05). ACI patients' poor prognosis after intravenous thrombolysis was observed to be independently associated with older age, higher admission NIHSS score, and elevated serum Fractalkine level (P<0.05), while elevated serum AHO3 level was found to be an independent protective factor for poor prognosis following intravenous thrombolysis in ACI patients (P<0.05), according to multivariate logistic regression analysis. When age and admission NIHSS score were taken into account, multivariate logistic regression analysis revealed that elevated serum AHO3 levels continued to be an independent protective factor for poor prognosis after intravenous thrombolysis in ACI patients (P<0.05) and elevated serum Fractalkine levels continued to be an independent risk factor for poor prognosis after intravenous thrombolysis in ACI patients (P<0.05). In patients with ACI, the prediction areas under the curve (AUCs) for serum AHO3, Fractalkine, and their combination for predicting a poor prognosis following intravenous thrombolysis were 0.799, 0.792, and 0.900, respectively, according to the results of the ROC curve study. The combined prediction AUC outperformed the individual prediction AUCs of Fractalkine (Z = 2.799, P = 0.027) and AHO3 (Z = 2.129, P = 0.034).
Conclusion The degree of ACI in patients is directly correlated with their serum levels of Fractalkine and AHO3. Following intravenous thrombolysis, individuals with ACI can have their prognosis evaluated using both of these signs, and their combination has a higher predictive value.
References
2.Nguyen NB, Nguyen Thi HH, Thi HL, Nguyen ST, Nguyen TV. The results of acute cerebral infarction treatment with hyperbaric oxygen therapy, 2020-2022. Int Marit Health. 2023;74(4):265-271. doi: 10.5603/imh.97720. PMID: 38111247.
3.Liu Y, Zhang Q, Yuan J, Chen X, Tao J, Chen B, Zhao W, Li G, Li Y, Liu D. [Acute cerebral infarction following extracorporeal membrane oxygenation treatment in patients with cardiogenic shock: 2 cases report and review of the literature]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Dec;35(12):1286-1290. Chinese. doi: 10.3760/cma.j.cn121430-20221011-00909. PMID: 38149391.
4.Zheng D, Li X, Fu Y. Risk factors for acute cerebral infarction in patients with primary hypertension. Ir J Med Sci. 2023 Oct;192(5):2441-2445. doi: 10.1007/s11845-022-03206-4. Epub 2022 Nov 19. PMID: 36401085.
5.Lyu Y, Xu B. Efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole in the treatment of acute cerebral infarction: A systematic review and meta-analysis. Medicine (Baltimore). 2024 Nov 1;103(44):e40223. doi: 10.1097/MD.0000000000040223. PMID: 39496028; PMCID: PMC11537593.
6.Li LD, Zhou Y, Shi SF. Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. Medicine (Baltimore). 2023 Mar 3;102(9):e32929. doi: 10.1097/MD.0000000000032929. PMID: 36862906; PMCID: PMC9981379.
7.Zhang L, Wei Y, Chen H, Ren H. Acute cerebral infarction following type B aortic dissection: A case report. Asian J Surg. 2024 Jun;47(6):2662-2664. doi: 10.1016/j.asjsur.2024.03.044. Epub 2024 Mar 27. PMID: 38548538.
8.Okubo S, Tamagawa T, Yamada M, Bannai T, Seki T, Usuki K, Shiio Y. Asymptomatic Acute Cerebral Infarction in a Patient with Hemoglobin Köln. Intern Med. 2024 Jul 1;63(13):1929-1932. doi: 10.2169/internalmedicine.2775-23. Epub 2023 Nov 20. PMID: 37981303; PMCID: PMC11272511.
9.Xie F, He Y, Sun LQ, Zheng H, Xie JX, Feng XS, Wang YF, Gan YH, Pan XR, Zhang YD, Wang PF, Li Y, Xiong XY. Acupuncture as an Adjunctive Therapy for Acute Cerebral Infarction: A Modified Delphi Consensus Study. Complement Med Res. 2025;32(4):301-313. doi: 10.1159/000547286. Epub 2025 Jul 5. PMID: 40618740.
10.Zhang S, Yang J. Factors influencing TCM syndrome types of acute cerebral infarction: A binomial logistic regression analysis. Medicine (Baltimore). 2023 Nov 17;102(46):e36080. doi: 10.1097/MD.0000000000036080. PMID: 37986281; PMCID: PMC10659613.
11.Rao Z, Tan W, Wang J, Zhou Y, Yang X, Hu S. Predictive value of Cmmi-MHR combined with thromboelastography parameters in acute cerebral infarction. BMC Med Imaging. 2024 May 18;24(1):115. doi: 10.1186/s12880-024-01299-0. PMID: 38762466; PMCID: PMC11102274.
12.Tan S, Liu Y, Li F, Han M, Ye M. The impact of various antiplatelet strategies on the incidence of gouty arthritis in hospitalized patients with acute cerebral infarction. Clin Neurol Neurosurg. 2024 Jul;242:108326. doi: 10.1016/j.clineuro.2024.108326. Epub 2024 May 13. PMID: 38772278.
13.He P, Li Z, Jiang H. Septic cavernous sinus thrombosis presenting as acute cerebral infarction and aneurysmal subarachnoid hemorrhage: Case report. Medicine (Baltimore). 2023 Nov 24;102(47):e36123. doi: 10.1097/MD.0000000000036123. PMID: 38013371; PMCID: PMC10681577.
14.Jin G, Han W, Duan T, Xue Z, Song C, Xu Y, Yu M. Edaravone dextranol alleviates ferroptosis, Cuproptosis, and blood‒brain barrier damage after acute cerebral infarction. Metab Brain Dis. 2025 Mar 3;40(3):134. doi: 10.1007/s11011-025-01559-0. PMID: 40029474.
15.Kamon T, Horie S, Inaba T, Ito N, Shiraki K, Ichikawa Y, Ezaki M, Shimpo H, Shimaoka M, Nishigaki A, Shindo A, Wada H. The Detection of Hypercoagulability in Patients with Acute Cerebral Infarction Using a Clot Waveform Analysis. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231161591. doi: 10.1177/10760296231161591. PMID: 36872898; PMCID: PMC9989368.
16.Jian H, Wang F, Wang Y, Dou L. Clinical Significance of MicroRNA-330-3p in Plasma Level for Acute Cerebral Infarction. Cerebrovasc Dis. 2024;53(4):411-419. doi: 10.1159/000533605. Epub 2023 Sep 29. PMID: 37778331.
17.Huang J, Liao F, Tang J, Shu X. Development of a model for predicting acute cerebral infarction induced by nonvariceal upper gastrointestinal bleeding. Clin Neurol Neurosurg. 2023 Dec;235:107992. doi: 10.1016/j.clineuro.2023.107992. Epub 2023 Sep 29. PMID: 37944305.
18.Du W, Fan L, Du J. Neuroinflammation-associated miR-106a-5p serves as a biomarker for the diagnosis and prognosis of acute cerebral infarction. BMC Neurol. 2023 Jun 27;23(1):248. doi: 10.1186/s12883-023-03241-3. PMID: 37369997; PMCID: PMC10294433.
19.Tian Y, Niu HT, Li MH, Wang YZ. Effect of VEGF on neurological impairment and prognosis of acute cerebral infarction patients: A retrospective case‒control study. Medicine (Baltimore). 2023 Feb 10;102(6):e29835. doi: 10.1097/MD.0000000000029835. PMID: 36820574; PMCID: PMC9907990.
20.Kwok CS, Abbas KS, Qureshi AI, Lip GYH. Outcomes for patients hospitalized with acute myocardial infarction and cerebral infarction in the United States: insights from the National Inpatient Sample. Intern Emerg Med. 2023 Mar;18(2):375-383. doi: 10.1007/s11739-022-03172-w. Epub 2023 Feb 7. PMID: 36746890.
21.Chen L, Liu F, Tian X, Zhang T, Zhang J, Ran F. Impact of cerebral microbleeds on cognitive functions and its risk factors in acute cerebral infarction patients. Neurol Res. 2023 Jun;45(6):564-571. doi: 10.1080/01616412.2022.2164456. Epub 2023 Jan 9. PMID: 36621968.
22.Zhu X, Sun X, Chai Q, Min L, Li H, Sun Y, Bu C. Dysregulation of Serum UCA1 and Its Clinical Significance in Patients with Acute Cerebral Infarction. Ann Clin Lab Sci. 2023 Sep;53(5):719-725. PMID: 37945010.
23.Yuqi Liu, Chengyong Wang, Yuanpeng Han. Management of Acute Cerebral Infarction by Intravenous Thrombolysis with Recombinant T-Cell Receptor and Plasminogen Activator and Association of Emergency Nursing Route in the Prognosis. Cell Mol Biol (Noisy-le-grand). 2023 Aug 31;69(8):18-24. doi: 10.14715/cmb/2023.69.8.3. PMID: 37715436.
24.Wang L, Zhang P, Xue J, Ma Q, Fu Y, Ou Y, Yuan X. Variability in sleep architecture and alterations in circadian rhythms in patients with acute cerebral infarction accompanied by sleep-disordered breathing. Sleep Breath. 2024 Oct;28(5):2017-2027. doi: 10.1007/s11325-024-03105-1. Epub 2024 Jul 16. PMID: 39012435.
25.Liang Z, Qiu L, Wang X, Feng L, Hao Y, Yang F, Ma D, Feng J. Effects of remote ischemic postconditioning on the pro-inflammatory neutrophils of peripheral blood in acute cerebral infarction. Aging (Albany NY). 2023 May 30;15(10):4481-4497. doi: 10.18632/aging.204751. Epub 2023 May 30. PMID: 37253636; PMCID: PMC10258025.
26.Shen Y, Li M, Wang S, Xia L, Ni X, Zhou L, Zhong J, Shi H, Dong Z. Comparison of the Efficacy and Safety Between Intravenous Thrombolysis, Direct Endovascular Therapy, and Bridging Therapy for Acute Basilar Artery Occlusion in Cerebral Infarction Patients. World Neurosurg. 2024 Jun;186:e206-e212. doi: 10.1016/j.wneu.2024.03.106. Epub 2024 Mar 26. PMID: 38537790.
27.Xu C, Zhan T. Study on rehabilitation effect of continuous nursing on patients with dysphagia in acute cerebral infarction. Medicine (Baltimore). 2025 Jul 11;104(28):e43141. doi: 10.1097/MD.0000000000043141. PMID: 40660601; PMCID: PMC12263028.
28.Ding SW, Wang JJ. Diagnostic value and clinical significance of lncRNA LINC01123 combined with fibrinogen in acute cerebral infarction. Clin Neurol Neurosurg. 2024 Jun;241:108309. doi: 10.1016/j.clineuro.2024.108309. Epub 2024 Apr 29. PMID: 38713963.
29.Hao H, Xing X, Li Y, Chu H, Zhao L, Cheng S, Liu Y, Wang T, Meng N, Duan R. Value evaluation of serum (sdLDLc*HCYc)/HDLc ratio in the stability of intracranial arterial plaques in patients with acute cerebral infarction. Acta Biochim Pol. 2023 Dec 7;70(4):911-917. doi: 10.18388/abp.2020_6817. PMID: 38060820.
30.Lin X, Wang W, Tao T, Zhang D, Mao L, He X. Synthetic role of miR-411-5p and CT perfusion information in predicting clinical outcomes after thrombolysis in acute cerebral infarction. Acta Neurol Belg. 2023 Apr;123(2):457-464. doi: 10.1007/s13760-022-02041-9. Epub 2022 Aug 6. PMID: 35933505.
Copyright (c) 2026 Dong Yun, Yu Wang, Peng Zuo, Shuai Deng, Fangfang Yan, Chai Jin, Zhou Wang

This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
